Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone furoate + levocabastine intranasal combination versus single agents in allergic rhinitis
2013-002940-94Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing Fluticasone furoate + levocabastine fixed-dose combination, Fluticasone furoate alone and Levocabastine alone (3 arms). Primary endpoint: TNSS on Day 8 after 8-day repeat dosing. Started Sep 2013; status: completed.
02
Drugs
fluticasonelevocabastine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2013-002940-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002940-94.